Literature DB >> 9244833

[Mineralocorticoid-induced hypertension].

J Hensen1, W Oelkers.   

Abstract

Several important advances have been made in the pathogenesis of mineralocorticoid induced hypertension. A hybrid gene was found to be responsible for glucocorticoid remediable hypertension. This extra gene contains fragments of 11-beta-hydroxylase and aldosterone synthase. The hybrid gene is the result of an unequal crossing-over of the two genes located in close proximity on chromosome 8, and leads to the production of aldosterone and the hybrid steroids 18-hydroxycortisol and 18-oxocortisol. These hybrid steroids are also detected in patients with aldosterone producing adenoma but not in patients with hyperaldosteronism due to bilateral adrenal hyperplasia. In Apparent "Mineralocorticoid Excess", inherited as an autosomal recessive disorder, an increased ratio of urinary cortisol metabolite to cortisone is diagnostic. The syndrome is due to a deficiency of the renal enzyme 11-beta-hydroxysteroid dehydrogenase type II, which protects the mineralocorticoid receptor against cortisol that binds to the mineralocorticoid receptor like aldosterone. Liddle's syndrome is a rare entity and due to a constitute activation of an aldosterone dependent protein which triggers the amiloride sensitive sodium channel in the kidney. This results in hypokalemic hypertension with suppressed aldosterone and renin levels.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9244833     DOI: 10.1007/bf03045082

Source DB:  PubMed          Journal:  Med Klin (Munich)        ISSN: 0723-5003


  24 in total

1.  [PRIMARY ALDOSTERONISM (CONN SYNDROME)].

Authors:  K R KOCZOREK
Journal:  Internist (Berl)       Date:  1964-01       Impact factor: 0.743

2.  Presidential address. I. Painting background. II. Primary aldosteronism, a new clinical syndrome.

Authors:  J W CONN
Journal:  J Lab Clin Med       Date:  1955-01

3.  The effect of age on prevalence of secondary forms of hypertension in 4429 consecutively referred patients.

Authors:  G H Anderson; N Blakeman; D H Streeten
Journal:  J Hypertens       Date:  1994-05       Impact factor: 4.844

4.  Computed tomographic scanning versus radioisotope imaging in adrenocortical diagnosis.

Authors:  C K Guerin; H W Wahner; C A Gorman; P C Carpenter; P F Sheedy
Journal:  Am J Med       Date:  1983-10       Impact factor: 4.965

5.  Adrenal sensitivity to angiotensin II and undiscovered aldosterone stimulating factors in hypertension.

Authors:  R D Brown; M Wisgerhof; P C Carpenter; G Brown; N S Jiang; P Kao; R Hegstad
Journal:  J Steroid Biochem       Date:  1979-07       Impact factor: 4.292

6.  Glucocorticoid-remediable aldosteronism in a large kindred: clinical spectrum and diagnosis using a characteristic biochemical phenotype.

Authors:  G M Rich; S Ulick; S Cook; J Z Wang; R P Lifton; R G Dluhy
Journal:  Ann Intern Med       Date:  1992-05-15       Impact factor: 25.391

7.  New aspects of mineralocorticoid hypertension.

Authors:  F Mantero; D Armanini; A Biason; M Boscaro; G Carpenè; F Fallo; G Opocher; S Rocco; C Scaroni; N Sonino
Journal:  Horm Res       Date:  1990

8.  A chimaeric 11 beta-hydroxylase/aldosterone synthase gene causes glucocorticoid-remediable aldosteronism and human hypertension.

Authors:  R P Lifton; R G Dluhy; M Powers; G M Rich; S Cook; S Ulick; J M Lalouel
Journal:  Nature       Date:  1992-01-16       Impact factor: 49.962

Review 9.  Renin-secreting tumors.

Authors:  P Corvol; F Pinet; P F Plouin; P Bruneval; J Menard
Journal:  Endocrinol Metab Clin North Am       Date:  1994-06       Impact factor: 4.741

Review 10.  Renal 11-beta-hydroxysteroid dehydrogenase: a mechanism ensuring mineralocorticoid specificity.

Authors:  C R Edwards
Journal:  Horm Res       Date:  1990
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.